|
|
Volumn 385, Issue 9985, 2015, Pages 2323-
|
|
Melanoma research gathers momentum
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IPILIMUMAB;
NIVOLUMAB;
ANTINEOPLASTIC AGENT;
CANCER IMMUNOTHERAPY;
CANCER INCIDENCE;
CANCER PREVENTION;
CANCER RESEARCH;
CANCER RISK;
CANCER SURVIVAL;
CUTANEOUS MELANOMA;
EDITORIAL;
GENE MUTATION;
GENETIC ASSOCIATION;
HEALTH CARE COST;
HEALTH PRACTITIONER;
HUMAN;
MOLECULAR BIOLOGY;
MOLECULARLY TARGETED THERAPY;
OVERALL SURVIVAL;
PATIENT EDUCATION;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RADIATION EXPOSURE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SKIN CANCER;
ULTRAVIOLET RADIATION;
AUSTRALIA;
DRUG COMBINATION;
IMMUNOTHERAPY;
INCIDENCE;
MEDICAL RESEARCH;
MELANOMA;
ORGANIZATION;
RISK REDUCTION;
SKIN NEOPLASMS;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
AUSTRALIA;
BIOMEDICAL RESEARCH;
CONGRESSES AS TOPIC;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOTHERAPY;
INCIDENCE;
MELANOMA;
PATIENT EDUCATION AS TOPIC;
RISK REDUCTION BEHAVIOR;
SKIN NEOPLASMS;
UNITED STATES;
|
|
EID: 84930922789
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(15)61087-X Document Type: Editorial |
|
Times cited : (24)
|
|
References (0)
|